July 29, 2020 / 11:43 AM / 12 days ago

BRIEF-GSK Could Maximize Target of 1 Bln Adjuvant Doses Based On Trial Data

July 29 (Reuters) - GlaxoSmithKline:

* CEO SAYS UNDERLYING DEMAND FOR ALL KEY GROWTH DRIVERS REMAINS STRONG - MEDIA CALL

* CEO SAYS WE DON’T EXPECT TO PROFIT FROM COVID-19 VACCINE PARTNERSHIPS IN THE PANDEMIC PHASE - MEDIA CALL

* CEO SAYS CO HAS NOT TAKEN ANY GOVERNMENT FUNDING ON ASO3 ADJUVANT AND HAS STARTED MANUFACTURING AT RISK - MEDIA CALL

* CEO, ON 1 BILLION TARGET DOSES OF ADJUVANT, SAYS CO WILL MAXIMIZE NUMBERS BASED ON DATA FROM TRIALS - MEDIA CALL Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below